Kite to present interim results from ZUMA-1 pivotal trial at ASH meeting
Kite Pharma announced that data from the interim analysis of the pivotal ZUMA-1 trial of KTE-C19 in patients with chemorefractory aggressive non-Hodgkin lymphoma have been accepted as an oral late-breaking presentation at the American Society of Hematology, or ASH, 58th Annual Meeting in San Diego, CA, on December 6, 2016. The abstract was one of only six accepted in this category and will be included in the December 1 online issue of Blood. Kite reports that KTE-C19 significantly improved Objective Response Rate in patients with Chemorefractory DLBCL at pre-defined interim analysis. "Outcomes for patients with aggressive NHL depend on whether their disease is sensitive to chemotherapy. The ZUMA-1 study was designed to support registration of KTE-C19 by enrolling a well-defined chemorefractory patient population. We are pleased with the outcome of the study to date and thank the patients and investigators for their participation in the first positive pivotal study in CAR-T therapy," said Jeff Wiezorek, M.D., Senior VP of Clinical Development of Kite.